Juliette Montanari

Ms. Juliette Montanari

Université de Caen Normandie, Caen, Normandie, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
AGAntoine Gilbert
Antoine Gilbert
MTMihaela Tudor
Mihaela Tudor
JMJuliette Montanari
Juliette Montanari
KCKevin Commenchail
Kevin Commenchail
DSDiana Savu
Diana Savu
François ChevalierFrançois Chevalier
François Chevalier
Chondrosarcoma is a malignant cartilaginous tumor that is particularly chemoresistant and radioresistant to X-rays. The first line of treatment is surgery, though this is almost impossible in some specific locations. Such resistances can be explained by the particular composition of the tumor, which develops within a dense cartilaginous matrix, producing a resistant area where the oxygen tension is very low. This microenvironment forces the cells to adapt and dedifferentiate into cancer stem cells, which are described to be more resistant to conventional treatments. One of the main avenues considered to treat this type of tumor is hadrontherapy, in particular for its ballistic properties but also its greater biological effectiveness against tumor cells. In this review, we describe the different forms of chondrosarcoma resistance and how hadrontherapy, combined with other treatments involving targeted inhibitors, could help to better treat high-grade chondrosarcoma.

8 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MCMathieu Césaire
Mathieu Césaire
JMJuliette Montanari
Juliette Montanari
HCHubert Curcio
Hubert Curcio
DLDelphine Lerouge
Delphine Lerouge
RGRadj Gervais
Radj Gervais
François ChevalierFrançois Chevalier
François Chevalier
Survival in unresectable locally advanced stage non-small cell lung cancer (NSCLC) patients remains poor despite chemoradiotherapy. Recently, adjuvant immunotherapy improved survival for these patients but we are still far from curing most of the patients with only a 57% survival remaining at 3 years. This poor survival is due to the resistance to chemoradiotherapy, local relapses, and distant relapses. Several biological mechanisms have been found to be involved in the chemoradioresistance such as cancer stem cells, cancer mutation status, or the immune system. New drugs to overcome this radioresistance in NSCLCs have been investigated such as radiosensitizer treatments or immunotherapies. Different modalities of radiotherapy have also been investigated to improve efficacity such as dose escalation or proton irradiations. In this review, we focused on biological mechanisms such as the cancer stem cells, the cancer mutations, the antitumor immune response in the first part, then we explored some strategies to overcome this radioresistance in stage III NSCLCs with new drugs or radiotherapy modalities.